PARIS--(BUSINESS WIRE)--Cytheris, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced expansion of the clinical trial program for CYT107, the company’s recombinant human Interleukin-7 (IL-7), with the initiation of a Phase I/IIa clinical trial in HIV patients. The trial will be conducted at sites in France, Italy, Canada and the United States and follows the launch of previously announced Phase I/IIa trials of IL-7 in Hepatitis C (HCV) and oncology. These trials also follow the successful completion of four Phase I studies and are designed to investigate IL-7’s potential for building immune system response.
